Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lemaitre Vascular (LMAT)
NASDAQ:LMAT
Holding LMAT?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.49Last Year’s EPS
$0.38Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: 4.38%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant sales and EPS growth, strong regional performance, and operational efficiency. However, there were challenges related to regulatory delays and filling sales rep positions. Despite these, the overall sentiment remains positive due to the substantial achievements in sales and margin improvements.Company Guidance
During the LeMaitre Vascular Q3 2024 earnings call, the company's executives provided updated guidance, highlighting several key metrics. They reported a 16% sales growth, driven by a 10% increase in pricing and 6% growth in unit volumes. The gross margin for Q3 was 67.8%, representing a 280 basis point increase year-over-year. The company projects a Q4 gross margin of 68%, with a full-year expectation of 68.3%, up 260 basis points from the previous year. Operating income for the quarter rose by 43% to $13.1 million, with an operating margin of 24%, and they expect to maintain this margin for the full year, up from 19% in 2023. LeMaitre also raised its Q4 sales and bottom-line estimates, anticipating 14% sales growth on a reported basis and 15% organically, with an EPS of $0.14 per share, up 30%. The company continues to focus on expanding its sales force, aiming for 155 to 160 sales reps by year-end, and has made significant progress in obtaining MDR CE marks, receiving 15 out of 22 sought.Strong Sales Growth
Achieved 16% sales growth in Q3 2024, led by grafts (24%), patterns (13%), and corona chunks (18%).
Earnings Per Share (EPS) Growth
Reported a 49% increase in EPS compared to the previous year.
Regional Sales Performance
APAC sales increased by 24%, EMEA by 22%, and the Americas by 12%.
Gross Margin Improvement
Gross margin increased to 67.8%, up 280 basis points year-over-year.
Operational Efficiency
Operating income rose by 43% year-over-year to $13.1 million, with an operating margin of 24%.
Success in China
Sales in China were up 62% in Q3 2024.
---
LMAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LMAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $88.25 | $94.73 | +7.34% |
| Aug 01, 2024 | $85.95 | $84.71 | -1.44% |
| May 02, 2024 | $66.40 | $73.81 | +11.16% |
| Feb 27, 2024 | $61.62 | $70.50 | +14.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lemaitre Vascular (LMAT) report earnings?
Lemaitre Vascular (LMAT) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Lemaitre Vascular (LMAT) earnings time?
Lemaitre Vascular (LMAT) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LMAT EPS forecast?
LMAT EPS forecast for the fiscal quarter 2024 (Q4) is $0.49.
---